Searchable abstracts of presentations at key conferences in endocrinology

ea0026p30 | Adrenal cortex | ECE2011

Is plasma mitotane level >30 mg/l a serious adverse event in patients with adrenocortical carcinoma (ACC)?: a retrospective analysis of the French COMETE network

Mauclere-Denost S M D , Tabarin A T , Drui D D , Chaillous L C , Salenave S S , Leboulleux S L , Chabre O C , Do-Cao C D C , Dubourg H D , Cuvelier M L C , Young J Y , Baudin E B

Background: Mitotane antitumor efficacy is related to plasma levels. Objective responses have been associated with mitotane plasma levels >14 mg/l. However, high plasma levels >20 or >30 mg/l are at higher risk of toxicity, especially neurotoxicity. National-based survey is lacking to evaluate the frequency and severity of high mitotane plasma levels. Our aim was to retrospectively describe serious adverse events (SAE).Methods: Mitotane plasm...

ea0027p58 | (1) | BSPED2011

Effect of diagnosing coeliac disease and instituting a gluten-free-diet on glycaemic control in asymptomatic children with type 1 diabetes mellitus

Sherif Marwan A A , Allison Gavin , Robertson Kenneth , Donaldson Malcolm D C

Background: Coeliac disease (CD) is common in children with type 1 diabetes mellitus, so that CD screening of all asymptomatic diabetic children is carried out in many medical centres. While introduction of a gluten-free diet (GFD) might improve glycaemic control, the burden of two dietary regimes could adversely affect compliance.Aim: To assess the short-term effect of the diagnosis and treatment of asymptomatic CD detected by screening on diabetic cont...

ea0031p166 | Neoplasia, cancer and late effects | SFEBES2013

Difficulties in management of malignant insulinoma

Garg A , Rathore A M , Patel D C , Khoo B , Caplin M , Meyer T

Introduction: Insulinomas are the most common, functioning, pancreatic neuro-endocrine tumours. The minority of patients <10% who present with metastatic disease have a median survival of <2 years.We present a case of a gentleman with a 30 years history of Multiple Endocrine neoplasia type 1 (MEN1), which highlights the various modalities of treatment and the challenges from his progressive disease and marked symptomatic hypoglycaemia.<p clas...

ea0029p341.1 | Cardiovascular Endocrinology and Lipid Metabolism | ICEECE2012

Cardiac hormones are dual inhibitors of vascular endothelial growth factor and the VEGFR2 receptor

Nguyen J P , Frost C D , Lane M L , Skelton W P , Skelton M , Vesely D L

Introduction: The growth of human tumors depends on the formation of new blood vessels and vascular endothelial growth factor (VEGF) helps control this process via inducing new capillaries to sprout from pre-existing blood vessels. Four cardiac hormones which eliminate up to 80% of human pancreatic cancers and up to 86% of human small-cell lung cancers growing in mice were investigated for their effects on VEGF and the VEGFR2/KDR/Flk-1 receptor. The VEGFR2 receptor is the main...

ea0081ep855 | Reproductive and Developmental Endocrinology | ECE2022

Maternal prolactin-levels in pregnancy and offspring body composition at 7 years. Odense Child Cohort

Pelck Hansen Freja , Grontved Anders , Jensen Richard C , D Hojsager Frederik , Brandslund Ivan , Boye Henriette , Jensen Tina Kold , Andersen Marianne , Glintborg Dorte

Background: Prolactin is associated with metabolic risk inside and outside of pregnancy. Maternal prolactin levels could be associated with offspring body composition.Aim: To investigate if maternal prolactin-levels were linked to offspring body composition at seven years of age.Design: Prospective observational cohort study (the Odense Child Cohort).Methods: Maternal fasting blood samples were assessed durin...

ea0026p699 | Diabetes complications | ECE2011

Gilbert syndrome and diabetes: a perfect union?

Matos M J , Souto S B , Oliveira A I , Silva S , Vinha E , Freitas P , Queiros J , Braga D C , Carvalho D

Introduction: Gilbert syndrome is one of the most common inherited diseases, with a prevalence of 5–7%. It is caused by a mutation in UGT1A1 gene, which is in turn responsible for a deficiency in bilirubin glucuronidation. It courses with unconjugated hyperbilirubinemia, and jaundice may occur in adolescence, after fasting, exercise, or in menses, and also with certain drugs. Individuals with Gilbert syndrome seem to have a reduction in the prevalence of micro- and macrov...

ea0024oc1.5 | Oral Communications 1 | BSPED2010

Factors affecting changes in insulin sensitivity and insulin secretion during Growth Hormone treatment in children born small for gestational age

Thankamony A , Jensen R B , O'Connell S , Kirk J M W , Donaldson M D C , Ivarsson Sten-A , Soder O , Hoey H , Juul A , Dunger D B

Background: Individuals born Small for Gestational age (SGA) are at high risk of development of type 2 diabetes. Growth hormone (GH) therapy can also adversely affect glucose metabolism.Aim: To explore the factors associated with changes in insulin sensitivity (IS) and insulin secretion during one year of GH treatment in children born SGA.Methods: In the NESGAS clinical trial, we studied 82 (55♂) pre-pubertal children (age 3....

ea0023oc1.5 | Oral Communications 1 | BSPED2009

The primordial growth disorder 3-M syndrome connects ubiquitination to the cytoskeletal adaptor obscurin-like 1

Hanson D , Murray P G , Sud A , Temtamy S A , Aglan M , Superti-Furga A , Holder S E , Urquhart J , Hilton E , Manson F D C , Scambler P , Black G C M , Clayton P E

3-M syndrome is an autosomal recessive primordial growth disorder characterized by pre- and post-natal growth restriction, facial dysmorphism and radiological abnormalities. Mutations in the gene CUL7 have been previously shown to cause 3-M syndrome. CUL7 is a member of the cullin family of E3 ubiquitin ligases involved in targeted protein degradation.We identified a large cohort of 3-M syndrome patients who did not carry CUL7 mutations but...

ea0077ec1.3 | Clinical Endocrinology Trust Best Abstract Clinical | SFEBES2021

Phase 3 and extension study of modified-release hydrocortisone in the treatment of congenital adrenal hyperplasia

Merke Deborah P , Mallappa Ashwini , Arlt Wiebke , De La Perriere Aude Brac , Hirschberg Angelica Linden , Juul Anders , Newell-Price John D C , Perry Colin Graham , Prete Alessandro , Rees Aled , Reisch Nicole , Stikkelbroeck Monica , Touraine Philippe A , Lewis Alexander , Maltby Kerry , Treasure Peter , Porter John , Ross Richard John M

Background: Patients with congenital adrenal hyperplasia (CAH) due to classic 21-hydroxylase deficiency have poor health outcomes. We compared disease control in CAH adults treated with modified release hydrocortisone (MRHC, Chronocort®, Diurnal Ltd) versus standard glucocorticoid (GC).Methods: 6-month, Phase 3 study in 122 patients randomised to either MRHC twice daily or standard GC followed by safety extension study on MRHC. Patients had 24-hr 17...